Glucagon Receptor Agonist¶

Quick Facts¶

Development Code	LY3437943
Peptide Class	Multi-Receptor Agonist (Triple Agonist)
Molecular Targets	GLP-1 Receptor (GLP-1R), GIP Receptor (GIPR), Glucagon Receptor (GCGR)
Amino Acid Length	39 amino acids (modified peptide derived from native incretin/glucagon sequences)
Half-Life	Approximately 6–7 days (once-weekly dosing)
Developer	Eli Lilly and Company
Current Development Phase	Phase 3 clinical trials (TRIUMPH program)
Primary Research Indications	Type 2 diabetes, obesity, non-alcoholic steatohepatitis (NASH/MASH), cardiovascular outcomes
Key Structural Feature	Fatty acid acylated peptide with balanced receptor activity across GLP-1R, GIPR, and GCGR

Executive Summary¶

Retatrutide (LY3437943) is an investigational synthetic peptide engineered as a first-in-class triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Developed by Eli Lilly and Company, retatrutide represents the most advanced expression of multi-receptor metabolic peptide pharmacology, evolving beyond the dual agonism paradigm established by tirzepatide.

By simultaneously activating three metabolically complementary receptor pathways, retatrutide achieves enhanced glycemic control, superior body weight reduction, and beneficial effects on hepatic steatosis through coordinated mechanisms spanning appetite suppression (GLP-1R), incretin potentiation (GIPR), and energy expenditure enhancement (GCGR). Phase 2 clinical data published in The New England Journal of Medicine and The Lancet have demonstrated substantial efficacy, with the 12 mg dose producing mean body weight reductions of 24.2% at 48 weeks — the largest weight reduction reported for any pharmacotherapeutic intervention to date, approaching the range typically associated with bariatric surgery.

The triple agonism approach validates the concept that coordinated activation of nutrient-regulated hormone pathways can produce metabolic benefits exceeding those of single or dual receptor agonists. The ongoing phase 3 TRIUMPH program is evaluating retatrutide across diabetes, obesity, MASH (metabolic dysfunction-associated steatohepatitis), and cardiovascular outcomes, with results anticipated to further define the clinical positioning of triple-receptor pharmacology. For researchers, retatrutide represents a critical test case for the multi-hormone polypharmacology paradigm in metabolic disease.

Background¶

The development of retatrutide emerged from a decade of conceptual and preclinical work establishing that the coordinated actions of multiple nutrient-regulated hormones produce more robust metabolic effects than any single pathway alone. Native GLP-1 is an incretin hormone secreted from intestinal L-cells that potentiates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. GIP, secreted from intestinal K-cells, similarly potentiates insulin secretion and additionally modulates adipose tissue lipid metabolism. Glucagon, secreted from pancreatic alpha cells, primarily acts to raise blood glucose through hepatic gluconeogenesis and glycogenolysis — a function that initially appeared counterproductive in a diabetes therapeutic.

The conceptual breakthrough came from the recognition that glucagon's catabolic actions — increased energy expenditure, enhanced fatty acid oxidation, and reduced hepatic triglyceride content — could be therapeutically harnessed if concurrently balanced by the glucose-lowering and insulinotropic effects of GLP-1 and GIP receptor activation. In 2015, Finan and colleagues at the Helmholtz Zentrum München and Indiana University published a landmark paper in Nature Medicine demonstrating that a rationally designed monomeric peptide triagonist incorporating balanced GLP-1R, GIPR, and GCGR activities corrected obesity and diabetes in rodents, producing weight loss superior to dual agonists and selective receptor agonists.

This foundational work, led by the Tschöp and DiMarchi laboratories, established the theoretical and experimental framework for multi-receptor metabolic pharmacology. Eli Lilly subsequently initiated a medicinal chemistry program to develop a clinical candidate with optimized receptor potency ratios, pharmacokinetic properties, and manufacturability. The result was LY3437943 (retatrutide), a 39-amino acid peptide with fatty acid acylation enabling once-weekly dosing and a carefully calibrated ratio of GIPR/GLP-1R/GCGR activities informed by extensive preclinical SAR optimization by Coskun and colleagues.

Core Science¶

Mechanism of Action¶

Retatrutide exerts its metabolic effects through the coordinated activation of three distinct class B G protein-coupled receptors, each contributing complementary mechanisms:

GLP-1 Receptor Activation: GLP-1R signaling in pancreatic beta cells potentiates glucose-dependent insulin secretion via the Gαs–cAMP–PKA–Epac2 pathway, enhancing Ca²⁺ influx and insulin granule exocytosis. In pancreatic alpha cells, GLP-1R activation suppresses glucagon secretion, further contributing to glycemic control. Central GLP-1R activation in the hypothalamic arcuate nucleus and brainstem area postrema produces profound appetite suppression and reduced food intake — the primary driver of body weight reduction. GLP-1R activation also delays gastric emptying, attenuating postprandial glycemic excursions.

GIP Receptor Activation: GIPR signaling complements GLP-1 effects through direct insulinotropic action on beta cells, particularly effective in the euglycemic state. GIPR activation in adipose tissue promotes lipid uptake and storage, improves insulin sensitivity, and may enhance the metabolic health of adipose depots. Emerging evidence suggests GIPR signaling in the central nervous system and gastrointestinal tract may attenuate the nausea and emetic responses associated with GLP-1R activation — a potential mechanistic basis for the improved tolerability observed with dual and triple agonists relative to pure GLP-1R agonists.

Glucagon Receptor Activation: GCGR stimulation acutely promotes hepatic glucose production, but in the context of concurrent GLP-1R and GIPR activation, the net effect is favorable. Chronic GCGR activation increases energy expenditure through enhanced thermogenesis in brown adipose tissue and increased fatty acid oxidation in the liver. GCGR signaling reduces hepatic triglyceride content, promotes mitochondrial biogenesis and function in hepatocytes, and stimulates hepatic FGF21 production — a hepatokine with beneficial metabolic effects. The combination of GLP-1R-mediated appetite suppression with GCGR-mediated increases in energy expenditure produces additive or synergistic effects on body weight that are not achievable through either pathway alone.

Receptor Pharmacology and Biased Signaling¶

Retatrutide binds to the extracellular domains of GLP-1R, GIPR, and GCGR with distinct affinity and efficacy profiles that reflect the physiological interplay of these hormone systems. The peptide engages Gαs-mediated cAMP production at all three receptors, while the profile of β-arrestin recruitment varies. Detailed signaling studies indicate that retatrutide exhibits biased agonism at the GLP-1R, with relatively greater cAMP production relative to β-arrestin-2 recruitment compared to native GLP-1. This biased signaling profile may contribute to the differentiated efficacy and tolerability profile observed in clinical studies, as GLP-1R-mediated β-arrestin recruitment has been implicated in adverse effects including nausea.

Pharmacokinetics and Structural Design¶

Retatrutide incorporates a fatty acid side chain conjugated via a linker to enable non-covalent binding to serum albumin. This albumin binding reduces renal clearance and protects against proteolytic degradation, extending the peptide's half-life to approximately 6–7 days and enabling therapeutic plasma concentrations with once-weekly subcutaneous administration. Preclinical pharmacokinetic studies demonstrated dose-proportional exposure and a volume of distribution consistent with primarily extracellular distribution. The peptide is eliminated through proteolytic degradation and renal clearance of metabolites.

Clinical Evidence¶

The phase 1 program established retatrutide's safety, tolerability, and pharmacokinetic profile in healthy volunteers and participants with type 2 diabetes, demonstrating dose-dependent reductions in body weight and glycemic parameters with an acceptable gastrointestinal tolerability profile.

The phase 2 type 2 diabetes trial enrolled 281 participants across five dose cohorts (0.5, 4, 8, and 12 mg maintenance doses, with 2 and 4 mg starting doses) and demonstrated significant reductions in HbA1c (up to −2.02% from baseline) and body weight (up to −16.5% from baseline) over 48 weeks. Importantly, the 12 mg dose arm showed glycemic efficacy comparable to or exceeding that of the most potent available GLP-1 receptor agonists.

The landmark phase 2 obesity trial, published by Jastreboff and colleagues in The New England Journal of Medicine, enrolled 338 adults with obesity or overweight with at least one weight-related condition. Results demonstrated mean body weight reductions of 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) at 48 weeks, compared to 2.1% for placebo. Notably, the weight reduction trajectory had not plateaued at 48 weeks in the 12 mg group, suggesting the potential for even greater efficacy with longer treatment duration. At the 12 mg dose, 100% of participants achieved ≥5% weight loss, 92% achieved ≥10%, and 63% achieved ≥20% — results unprecedented in obesity pharmacotherapy.

Research Evidence¶

Finding	Data	Source
Weight reduction (phase 2 obesity, 12 mg, 48 weeks)	−24.2% from baseline	N Engl J Med. (2023)
HbA1c reduction (phase 2 T2D, 12 mg, 48 weeks)	−2.02% from baseline	Lancet. (2023)
≥20% weight loss (12 mg, 48 weeks)	63% of participants	N Engl J Med. (2023)
Hepatic fat fraction reduction (MRI-PDFF)	−82% relative reduction at 8 mg	N Engl J Med. (2023)
HbA1c <7.0% achievement (12 mg, 48 weeks)	87% of participants	Lancet. (2023)
Energy expenditure (preclinical, GCGR component)	+12–15% increase in DIO mice	Nat Med. (2015)
Waist circumference reduction (12 mg)	−17.1 cm	N Engl J Med. (2023)
Triglyceride reduction (12 mg)	−37.5%	N Engl J Med. (2023)
Nausea incidence (12 mg)	45% (predominantly mild-moderate)	N Engl J Med. (2023)
Half-life (subcutaneous)	6–7 days	Lancet. (2022)
β-arrestin bias at GLP-1R	Reduced β-arrestin-2 recruitment vs GLP-1	Diabetes Obes Metab. (2022)
Dose proportionality (AUC, 0.5–12 mg)	Linear pharmacokinetics	Lancet. (2022)

FAQ¶

Q: What distinguishes retatrutide from tirzepatide?

A: Retatrutide adds glucagon receptor (GCGR) agonism to the GIPR/GLP-1R dual agonism of tirzepatide. This triple-receptor approach is designed to further increase energy expenditure and hepatic lipid oxidation beyond what dual agonism alone can achieve. In phase 2 trials, retatrutide produced mean weight reductions of 24.2% compared to approximately 20.9% for tirzepatide in separate phase 3 trials — though direct head-to-head comparisons have not been conducted. The addition of GCGR activation also appears to produce greater reductions in hepatic fat.

Q: How does retatrutide achieve once-weekly dosing?

A: Retatrutide incorporates a fatty acid side chain that binds non-covalently to serum albumin. This albumin binding serves two critical functions: it reduces renal clearance by keeping the peptide above the glomerular filtration threshold, and it protects the peptide from proteolytic degradation by shielding susceptible cleavage sites. The resulting half-life of approximately 6–7 days enables stable therapeutic plasma concentrations with once-weekly subcutaneous administration.

Q: What weight reduction has been observed with retatrutide?

A: In the phase 2 obesity trial published in the New England Journal of Medicine, participants receiving retatrutide 12 mg once weekly experienced mean body weight reductions of 24.2% at 48 weeks. This represents the largest weight reduction ever reported for a pharmacotherapeutic intervention. By comparison, the highest doses of semaglutide (2.4 mg) and tirzepatide (15 mg) produced mean reductions of approximately 14.9% and 20.9% in their respective pivotal trials. Notably, weight loss had not plateaued at 48 weeks, suggesting further reduction with extended treatment.

Q: What are the primary adverse effects reported?

A: Gastrointestinal adverse effects — nausea (45% at 12 mg), diarrhea (32%), vomiting (26%), and constipation (21%) — are the most commonly reported events, consistent with the GLP-1 receptor agonist class. These effects are predominantly mild to moderate in severity and tend to diminish with continued dosing as tolerance develops. The incidence of gastrointestinal events appears comparable to or slightly higher than tirzepatide but is managed through gradual dose escalation. Cardiac arrhythmias (mild increases in heart rate) and injection-site reactions have also been reported.

Q: Why include glucagon receptor agonism if glucagon raises blood glucose?

A: While glucagon does acutely stimulate hepatic glucose production, concurrent GLP-1R activation (which stimulates insulin secretion and suppresses endogenous glucagon) and GIPR activation effectively counteract this hyperglycemic effect. This allows the beneficial catabolic actions of GCGR activation — increased energy expenditure, enhanced fatty acid oxidation, reduced hepatic steatosis — to be realized without net glucose elevation. The net effect is improved glycemic control with substantially greater weight loss, a combination not achievable through GLP-1R agonism alone.

Q: Is retatrutide being studied for MASH (formerly NASH)?

A: Yes. The glucagon receptor agonism component is hypothesized to reduce hepatic steatosis through increased fatty acid oxidation and enhanced mitochondrial function in hepatocytes. In the phase 2 obesity trial, retatrutide produced an 82% relative reduction in hepatic fat fraction (measured by MRI-PDFF) at the 8 mg dose. The TRIUMPH phase 3 program includes a dedicated MASH trial evaluating histological outcomes including steatosis, inflammation, and fibrosis. Retatrutide is also being investigated for potential antifibrotic effects mediated through GCGR-stimulated hepatic FGF21 production.

Q: How does the biased signaling profile of retatrutide affect its pharmacology?

A: Retatrutide exhibits biased agonism at the GLP-1R, showing relatively greater activation of Gαs-mediated cAMP signaling relative to β-arrestin-2 recruitment when compared to native GLP-1. This biased signaling profile is potentially significant because GLP-1R-mediated β-arrestin recruitment has been implicated in nausea and emetic responses, while cAMP signaling drives the beneficial metabolic effects. Preclinical data suggest that GLP-1R agonists with reduced β-arrestin recruitment exhibit improved gastrointestinal tolerability at equivalent glycemic efficacy, though this hypothesis requires clinical validation.

Q: What is the dosing schedule used in clinical trials?

A: Clinical trials employ a dose-escalation regimen over approximately 16–24 weeks to improve gastrointestinal tolerability. Participants start at 2 mg once weekly and escalate through intermediate doses (4 mg, 8 mg) to target maintenance doses of 4, 8, or 12 mg. The gradual escalation allows the gastrointestinal system to adapt to increasing GLP-1R activation, substantially reducing the severity and duration of nausea and other GI adverse events. Dose reductions are permitted for tolerability, similar to the tirzepatide dosing paradigm.

Q: What are the current limitations of retatrutide research?

A: Current limitations include: (1) the relatively short duration of published clinical data (≤48 weeks), though phase 3 data will extend this; (2) absence of completed cardiovascular outcomes data (the TRIUMPH-CVOT trial is ongoing); (3) need for larger and more diverse participant populations including those with severe obesity and multiple comorbidities; (4) limited understanding of effects on lean body mass composition and potential for sarcopenic obesity; (5) durability of weight loss after treatment cessation; and (6) long-term safety data beyond 2 years of continuous treatment.

Q: How does retatrutide compare to bariatric surgery in terms of efficacy?

A: The 24.2% mean weight reduction observed with retatrutide 12 mg at 48 weeks approaches the range typically reported after sleeve gastrectomy (25–30% total body weight loss) and exceeds that of adjustable gastric banding (15–20%). This represents a milestone in pharmacotherapy, as no previous medication has demonstrated efficacy approaching surgical benchmarks. However, the trajectory of surgical weight loss typically extends beyond 48 weeks, and retatrutide's long-term durability has not been established beyond this timeframe. Direct comparative trials between retatrutide and bariatric surgery have not been conducted.

References¶

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor triagonist, for people with type 2 diabetes: a phase 2 randomised trial. Lancet. 2023;402(10411):1393-1405. doi:10.1016/S0140-6736(23)01553-2
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, multiple-ascending-dose trial. Lancet. 2022;400(10357):1869-1881. doi:10.1016/S0140-6736(22)02033-5
Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. doi:10.1038/nm.3761
Coskun T, Sloop KW, Loghin C, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for the treatment of obesity and diabetes: from discovery to clinical proof of concept. Diabetes Obes Metab. 2022;24(4):684-693. doi:10.1111/dom.14629
Galsgaard KD, Pedersen J, Knop FK, et al. Glucagon receptor signaling and lipid metabolism. Front Physiol. 2019;10:413. doi:10.3389/fphys.2019.00413
Capozzi ME, DiMarchi RD, Tschöp MH, et al. Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev. 2018;39(5):719-738. doi:10.1210/er.2018-00117
Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-420. doi:10.1016/j.tem.2020.02.006
Tschöp MH, DiMarchi RD. Single-molecule combinatorial therapeutics for treating obesity and diabetes. Diabetes. 2017;66(7):1766-1769. doi:10.2337/dbi16-0086
Sonne DP, Hemmingsen B, Faber J, et al. Pharmacology and physiology of glucagon receptor signaling. Mol Metab. 2021;46:101169. doi:10.1016/j.molmet.2021.101169
Henderson SJ, Konkar A, Hornigold DC, et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab. 2016;18(12):1176-1190. doi:10.1111/dom.12735
Jones B, Buenaventura T, Kanda N, et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat Commun. 2018;9(1):1602. doi:10.1038/s41467-018-03941-2
Pocai A. Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014;3(3):241-251. doi:10.1016/j.molmet.2013.12.001
Müller TD, Finan B, Clemmensen C, et al. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721-766. doi:10.1152/physrev.00025.2016
Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-757. doi:10.1038/nchembio.209

About RPL Peptide: RPL Peptide is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptide Data Center.

— Written by the RPL Scientific Editorial Team | Last updated August 2025